52.78 USD
↗ 0.06 (0.11%)AT CLOSE (11:59 AM EDT)
Terns Pharmaceuticals, Inc. Common Stock
TERNNASDAQ • USD
52.78
↘ 0.15 (0.28%)
POST MARKET (AS OF 04:53 PM EDT)
Post Market
AS OF 04:53 PM EDT
52.78
↘ 0.15 (0.28%)
Market: OPEN
Open?$52.73
High?$52.82
Low?$52.70
Prev. Close?$52.72
Volume?6.1M
Avg. Volume?6.8M
VWAP?$52.75
Rel. Volume?0.90x
Bid / Ask
Bid?$45.33 × 100
Ask?$60.14 × 100
Spread?$14.81
Midpoint?$52.74
Valuation & Ratios
Market Cap?6.1B
Shares Out?115.4M
Float?55.5M
Float %?63.5%
P/E Ratio?N/A
P/B Ratio?6.05
EPS?-$0.83
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?62.41Strong
Quick Ratio?62.41Strong
Cash Ratio?31.98Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score83/100
P/E?N/A▾
P/B?6.05FAIR▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-50.5CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-9.6%WEAK▾
ROA?-9.4%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$5.6B
Related Companies
Loading...
News
Profile
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.
Employees
59
Market Cap
6.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-02-05
Address
1065 EAST HILLSDALE BLVD., SUITE 100
FOSTER CITY, CA 94404
Phone: 650-525-5535 EXT.101
FOSTER CITY, CA 94404
Phone: 650-525-5535 EXT.101